Category Archives: Innovation

US Bill on drug prices: Improving Access to Affordable Prescription Drugs Act

Source: www.franken.senate.gov A bill on drug prices has been introduced in US Congress to bring down prescription drug prices. The Improving Access to Affordable Prescription Drugs Act aims to ensure that drug companies put patients before profits and bring relief to families … Continue reading

Posted in Drug prices, Innovation, Transparency, Uncategorized | Leave a comment

In India’s Fight Against Tuberculosis, Diagnostics Remains Poorly Understood

A lack of innovation in diagnostics is making Indians more prone to drug-resistant TB, which is difficult to treat and could be fatal. By Ankur Paliwal, The Wire | March 3, 2017 The end of an otherwise typical day in the winter of … Continue reading

Posted in Innovation, Patent, Uncategorized | Tagged | Leave a comment

Patent denied, price of prostate cancer drug may go down

The Indian Patent Office recently denied a patent for the drug Xtandi (Enzalutamide) by Japanese firm Astellas Pharma used in  treatment of prostate cancer. This decision comes in the light of the pre-grant opposition filed by pharma companies BDR Pharma, drug … Continue reading

Posted in Bayh Dole Act, March in rights, Patent, Patent Opposition, Sec 3 (d), Uncategorized | Tagged | Leave a comment

The U.S. Is Standing in the Way of Cheaper Drugs for the Poor

By JASON CONE and RAYMOND C. OFFENHEISER, The New York Times|OCT. 27, 2016 Every few months, a drug company gets caught cranking up prices. Most recently, Mylan, the maker of EpiPen, took its turn in the hot seat for raising the … Continue reading

Posted in Innovation, R&D, TPP, Uncategorized, UNHLP report, WHO | Leave a comment

Just the Medicine

How the next president can lower drug prices with the stroke of a pen. By Alicia Mundy, Washington Monthly | Nov/Dec 2016 It’s hard to watch television or read a newspaper these days without seeing stories about outrageous prescription drug … Continue reading

Posted in Bayh Dole Act, Drug prices, Patent, R&D, Uncategorized | Leave a comment

UN High Level Panel report is good prescription for change in access to medicines

Source: PharmaLetter | October 18, 2016 In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General’s High-Level Panel report on Access to Medicines and looks at the … Continue reading

Posted in Delinkage, R&D, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Indian drug regulator may scrap licence renewal; move may affect quality of medicines

By Prabha Raghavan, ET Bureau | October 8, 2016 NEW DELHI: India’s drug regulator proposes to scrap the renewal of licences and approvals for manufacturing and selling drugs and cosmetics in the country as part of efforts to remove hurdles … Continue reading

Posted in Clinical Trials, Uncategorized | Leave a comment